GEBRO and Spektus Partner for ActraFlex Commercialization
GEBRO Holding and Spektus Pharma have established a global commercialisation partnership for ActraFlex, an extended-release…
Newswire
Alamar and Nightingale Health Launch UK Biobank Neurodegeneration Study
Alamar Biosciences and Nightingale Health have announced the UK Biobank Proteomics for Risk Identification and…
Servier’s $1.55 Billion Muscular Dystrophy Drug Fails Key Trial
The French pharma Servier announced that its experimental drug, sevasemten, has failed to demonstrate efficacy…
Vertex Addresses Concerns Over Kidney Drug Launch
On a conference call, executives at Vertex Pharmaceuticals expressed confidence in the upcoming launch of…
FDA Requires Drug Establishment Registration
Establishments engaged in manufacturing, repacking, relabeling, or salvaging drugs for U.S. distribution are required to…
Recursion Plans H2 2027 Trial for REC-4881 After Positive FAP Data
Recursion expects to launch its first registrational trial in the second half of 2027 for…
FDA Calls for Stronger Potency Upkeep in CGT Manufacturing
The FDA’s CBER director emphasized the need for stronger potency maintenance in cell and gene…
AbbVie Inks $757M Migraine-Focused Deal with Brise Pharmaceuticals
AbbVie and Brise Pharmaceuticals have shared details on a migraine-focused deal valued at $757 million.…
Compass Pathways Leads Race for First Psychedelic Approval
Compass Pathways is considered a frontrunner in the race to obtain the first approval for…
MadeAi Launches AI Platform for Dossier Development
MadeAi has launched an artificial intelligence platform called MadeAi Dossier Expert, aimed at assisting pharmaceutical…